Indo US Bio-Tech (NSE:INDOUS) Other Stockholders Equity: ₹725 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INDOUS Indo US Bio-Tech Ltd NSE:INDOUS
64 GF Score
Price ₹86.65
GF Value ₹314.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Indo US Bio-Tech Other Stockholders Equity?

Indo US Bio-Tech NSE:INDOUS +0.97% 64 Other Stockholders Equity is ₹725 Mil as of Mar. 2026. GuruFocus rates NSE:INDOUS with a GF Score™ of 64/100 and a GF Value™ of ₹314.15 (Possible Value Trap). The stock has 5 warning signs investors should review.

Indo US Bio-Tech's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹725 Mil.

Indo US Bio-Tech's quarterly Other Stockholders Equity declined from Sep. 2025 (₹666 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹725 Mil).

Indo US Bio-Tech's annual Other Stockholders Equity increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) and increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹725 Mil).

Indo US Bio-Tech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Indo US Bio-Tech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo US Bio-Tech Other Stockholders Equity Chart

Indo US Bio-Tech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.18 0.23 724.82

Indo US Bio-Tech Quarterly Data
Mar20 Sep20 Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.00 666.17 0.00 724.82
NSE:INDOUS
64GF Score
Indo US Bio-Tech Ltd NSE:INDOUS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo US Bio-Tech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹725 Mil mean?
Indo US Bio-Tech (NSE:INDOUS) has a Other Stockholders Equity of ₹725 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Indo US Bio-Tech and its competitors.
Is Indo US Bio-Tech's Other Stockholders Equity too high?
Indo US Bio-Tech's current Other Stockholders Equity is ₹725 Mil. Overall, Indo US Bio-Tech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Other Stockholders Equity compare to CTVA and CF?
Indo US Bio-Tech's Other Stockholders Equity of ₹725 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for an Agriculture company?
A good Other Stockholders Equity depends on the Agriculture industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Indo US Bio-Tech and its competitors. Indo US Bio-Tech's current Other Stockholders Equity is ₹725 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹314.15, compared to a current price of ₹86.65 — trading 72.4% below its estimated fair value. The current Other Stockholders Equity is ₹725 Mil. Indo US Bio-Tech's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Other Stockholders Equity is ₹725 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?

Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued. The current stock price of ₹86.65 is trading 72.4% below its estimated GF Value™ of ₹314.15. GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.

Key valuation signals for NSE:INDOUS:

  • Other Stockholders Equity: ₹725 Mil
  • GF Value™: ₹314.15 vs. price of ₹86.65 (72.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indo US Bio-Tech Business Description

Other Exchanges 541304:India
Address Satadhar Char Rasta, Sola Road, 309, Shanti Mall, Opposite Navrang Tower, Ahmedabad, GJ, IND, 380061
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
64GF Score

Get the complete analysis for NSE:INDOUS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹86.65
Price
₹314.15
GF Value